Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage chemotherapy plus activated NK cells in relapsed/refractory pediatric T-cell lymphoblastic leukemia/lymphoma
2012-000054-63Phase 2Terminated
- Sponsor
- Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús
- Start
- Jan 2012
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NK cell therapy (Anhui Provincial Hospital) in t-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LL), sponsored by Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús. Primary endpoint: Safety of NK cell infusion after chemotherapy. Started Jan 2012; status: terminated.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2012-000054-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000054-63.